Spontaneous reporting of rare events associated with atypical antipsychotics using the FDA adverse event reporting system

被引：0
|
作者：
Emechebe, Nnadozie [1 ]
Mukhtar, Fahad [1 ,2 ]
Scheer, Darren [1 ,3 ]
Patel, Arshiya [4 ]
Wadhawan, Abhishek [2 ]
Schwartz, Skai [1 ]
Zgibor, Janice [1 ]
机构：
[1] Univ S Florida, Coll Publ Hlth, Dept Epidemiol & Biostat, Tampa, FL USA
[2] St Elizabeth Hosp, Psychiat Residency Training Program, Washington, DC USA
[3] Biotech Res Grp Corp, Tampa, FL USA
[4] Univ S Florida, Dept Global Hlth, Coll Publ Hlth, Tampa, FL USA
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2019年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
709
引用
收藏
页码：345 / 346
页数：2
相关论文
共 50 条
  • [1] Evaluation of atypical antipsychotics associated rhabdomyolysis using the FDA adverse event reporting system database
    Yin, Yi
    Jiang, Jie
    Jin, Youpeng
    SCIENTIFIC REPORTS, 2025, 15 (01):
  • [2] Adverse events associated with carbamazepine: a pharmacovigilance study using the FDA Adverse Event Reporting System
    Huang, Shulan
    Dong, Hanlin
    Luo, Dongqiang
    Jiang, Jiazhen
    Liu, Manting
    Wu, Jiayu
    Dou, Xiangyun
    Zhou, Siyuan
    EXPERT OPINION ON DRUG SAFETY, 2024,
  • [3] A Review of Dental Adverse Events Using the FDA Adverse Event Reporting System
    Altman, Keith
    Budny, Renata
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2014, 23 : 400 - 400
  • [4] Assessing taxane-associated adverse events using the FDA adverse event reporting system database
    Lao, Dong-Hui
    Chen, Ye
    Fan, Jun
    Zhang, Jian-Zhong
    CHINESE MEDICAL JOURNAL, 2021, 134 (12) : 1471 - 1476
  • [5] Vedolizumab Adverse Events: Analysis of the FDA Adverse Event Reporting System
    Jow, Steven
    Hutfless, Susan
    INFLAMMATORY BOWEL DISEASES, 2017, 23 : S35 - S36
  • [6] Reports of adverse events related with second generation antipsychotics in children in the FDA adverse event reporting system (FAERS)
    Zapata, Lorenzo Villa
    Bibbs, Janese
    Crapps, Mariah
    Lumbreras, Ainhoa Gomez
    Malone, Daniel
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 579 - 580
  • [7] Adverse events associated with brolucizumab: a disproportionality analysis of the FDA adverse event reporting system (FAERS)
    Xiong, Xiaomei
    Zhang, Xiuwen
    Li, Xiaoxia
    Huang, Taomin
    EXPERT OPINION ON DRUG SAFETY, 2024, 23 (11) : 1447 - 1452
  • [8] Fosfomycin-associated adverse events: A disproportionality analysis of the FDA Adverse Event Reporting System
    Yang, Luxuan
    Zhang, Wenyong
    Shen, Xiujuan
    Liu, Meiqin
    Wu, Meiying
    Xiao, Dan
    DRUG DISCOVERIES AND THERAPEUTICS, 2025,
  • [9] Cardiac adverse events associated with quetiapine: Disproportionality analysis of FDA adverse event reporting system
    Shu, Yamin
    Ding, Yiling
    Liu, Lulu
    Zhang, Qilin
    CNS NEUROSCIENCE & THERAPEUTICS, 2023, 29 (09) : 2705 - 2716
  • [10] A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS)
    Shu-peng Zou
    Hai-yun Yang
    Meng-ling Ouyang
    Qian Cheng
    Xuan Shi
    Ming-hui Sun
    BMC Pharmacology and Toxicology, 24
12345